CYTOKINETICS INC: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in Cytokinetics Inc via a Schedule 13G filing with the SEC (accession 0000093751-26-000641). The passive-investment disclosure signals renewed institutional interest in the biopharmaceutical company. The exact share count and percentage were not detailed in the headline filing summary. Investors will watch for the full filing to confirm the precise size of the position and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Cytokinetics Inc